U.S CAR-T Cell Therapy Market to hit US$ 9.85 billion by 2033: Growth Drivers, Key Players & Investment Opportunities

US CAR-T cell therapy market size reached US$ 3.42 billion in 2024 from US$ 3.07 billion in 2023 and is expected to reach US$ 9.85 billion by 2033, growing at a CAGR of 12.7% during the forecast period 2025-2033.

In the U.S., FDA-approved CAR-T therapies remain highly expensive. CD19-targeted treatments like Kymriah (Novartis) and Yescarta (Gilead/Kite) cost roughly $373,000 to $475,000 per infusion, while BCMA-targeted options such as Abecma and Carvykti for multiple myeloma are priced above $450,000 to $465,000. When hospitalization and post-treatment care are included, total costs can exceed $1 million per patient.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/us-car-t-cell-therapy-market?kb

Latest M&A

Gilead Sciences acquired Interius BioTherapeutics for $350 million, expanding Kite Pharma's in vivo CAR-T therapy capabilities beyond the current ex vivo platforms like Yescarta and Tecartus.​

Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion, with Orbital developing next-generation in vivo CAR-T technologies for cancers including hematologic malignancies.

Key Players:

Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb company, Johnson & Johnson, and Autolus, Inc.

Latest Drugs and Product Launches

FDA-approved CAR-T therapies such as CARVYKTI (ciltacabtagene autoleucel), ABECMA (idecabtagene vicleucel), Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel) continue to dominate US treatment for relapsed/refractory hematologic cancers.​

Next-generation CAR-T products in late-stage clinical development include Arcellx's Anito-cel, Novartis' PHE885, and Bristol-Myers Squibb's BMS-986393 targeting multiple myeloma and B-cell lymphomas.

Growth Forecast Projection:

The Global US CAR-T Cell Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global US CAR-T Cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=us-car-t-cell-therapy-market?kb

Key Segmentation:

By Therapy Type: (Allogeneic CAR-T Cell Therapy and Autologous CAR-T Cell Therapy)

By Target Antigen: (CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, and Others)

By Application: (Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, and Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest Project Hubs

US-based centers of excellence in CAR-T research and manufacturing include Houston's Baylor College of Medicine, Seattle's Fred Hutchinson Cancer Research Center, and multiple sites focusing on commercial-scale CAR-T production.​

Japan's CAR-T therapy ecosystem is expanding with government-funded infrastructure and partnerships with global biotech to accelerate therapy access and indigenous innovation.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/us-car-t-cell-therapy-market?kb

Latest Investments

✅ Luminary Therapeutics received $5.8 million from ARPA-H for developing solid tumor CAR-T therapies in the US, highlighting strategic government funding support.​

✅ Wugen raised $115 million in August 2025 for off-the-shelf allogeneic CAR-T development, underscoring investor confidence in "off-the-shelf" CAR-T platforms.​

✅ The Japanese government supports advanced CAR-T product development and regulatory facilitation, fueling market forecast to nearly double from approx. JPY 20 billion in 2024 to JPY 39 billion (~USD 280 million) by 2030.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/us-car-t-cell-therapy-market?kb

Latest Clinical Trials

✅ Paradromics obtained FDA approval for clinical trials of their in vivo CAR-T for speech restoration, progressing cutting-edge neurological indication CAR-T studies in the US.​

✅ Numerous US trials focus on optimizing CAR-T therapies for hematological malignancies and expanding into solid tumors, targeting novel antigens and dual-target CAR-T combinations.​

✅ In Japan, multiple clinical trials evaluate safety and efficacy of approved CAR-T therapies in diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), and ongoing pipeline extensions

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.